Top Markets
#1 DogBull DogBull +107.80%
#2 MarsCoin MarsCoin +66.03%
#3 ADO Protocol ADO Protocol +52.00%
#4 Siacoin Siacoin +44.32%
#5 Ontology Gas Ontology Gas +24.48%
#6 The Bitcoin Bull The Bitcoin Bull +17.38%
#7 Apertum Apertum +14.83%
#8 Useless Coin Useless Coin +14.74%
#9 UnifAI Network UnifAI Network +10.76%
#10 Velo Velo +10.46%
Coin of the day
DogBull DogBull
Settings
Language
ENGLISH
Currency
USD
Theme
BioAge Labs Inc. BioAge Labs Inc.

BioAge Labs Inc.

BIOA
Rank in Stocks #15445
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops... BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Share Price
$9.34
Last synced: 2026-08-31
Market Cap
$351.70M
Change (1 day)
-3.20%
Change (1 year)
89.48%
Country
US
Trade BioAge Labs Inc. (BIOA)

Category

Healthcare
Revenue for BioAge Labs Inc. (BIOA)
Revenue in Sep 2026 TTM: 0
According to BioAge Labs Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for BioAge Labs Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH